Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sapropterin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAH known ✓ | P00439 | 1/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | NOS1 | P29475 | 10/20 | 0.97 |
| ▸ | CASP7 | P55210 | 2/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.97 |
| ▸ | USP2 | O75604 | 1/20 | 0.97 |
| ▸ | NOS3 | P29474 | 3/20 | 0.61 |
| ▸ | NOS2 | P35228 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RGS12 | O14924 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sapropterin SCHEMBL31106620 | 1.00 | KDM4E (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 | |
| Sapropterin SCHEMBL1070424 | 1.00 | KDM4E (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 | |
| Sapropterin SCHEMBL29059706 | 0.99 | NOS1 (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 | |
| Sapropterin SCHEMBL260185 | 0.99 | NOS1 (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 | |
| Sapropterin SCHEMBL29538547 | 0.99 | NOS1 (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 | |
| Sapropterin SCHEMBL14072498 | 0.99 | NOS1 (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 | |
| Sapropterin SCHEMBL7942378 | 0.99 | NOS1 (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 | |
| Sapropterin SCHEMBL14401407 | 0.99 | NOS1 (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 | |
| Sapropterin SCHEMBL21068033 | 0.99 | NOS1 (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 | |
| Sapropterin SCHEMBL29351671 | 0.99 | NOS1 (1.00) | KDM4EMAPTBLMKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025230907-A1 | A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-06 | — | — | WO | claimed |
| EP-4426274-A1 | NITRIC OXIDE DONORS FOR USE IN SURGICAL RECOVERY | Baxter International Inc. (US) | 2024-09-11 | — | — | EP | claimed |
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | KEEFER, Edward (US) | 2024-08-29 | — | — | US | claimed |
| US-11969522-B2 | Use of immune modulators to improve nerve regeneration | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-30 | — | — | US | claimed |
| WO-2023081681-A1 | NITRIC OXIDE DONORS FOR USE IN SURGICAL RECOVERY | BAXTER INTERNATIONAL INC. (US) | 2023-05-11 | — | — | WO | claimed |
| US-20230140515-A1 | NITRIC OXIDE DONORS FOR USE IN SURGICAL RECOVERY | BAXTER INTERNATIONAL INC. | 2023-05-04 | — | — | US | claimed |
| WO-2025230907-A1 | A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-06 | — | — | WO | disclosed |
| EP-4426274-A1 | NITRIC OXIDE DONORS FOR USE IN SURGICAL RECOVERY | Baxter International Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | KEEFER, Edward (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240269343-A1 | USE OF IMMUNE MODULATORS TO IMPROVE NERVE REGENERATION | NERVES INC (US) | 2024-08-15 | — | — | US | disclosed |
| WO-2023081681-A1 | NITRIC OXIDE DONORS FOR USE IN SURGICAL RECOVERY | BAXTER INTERNATIONAL INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230140515-A1 | NITRIC OXIDE DONORS FOR USE IN SURGICAL RECOVERY | BAXTER INTERNATIONAL INC. | 2023-05-04 | — | — | US | disclosed |
| EP-3996703-A1 | USE OF IMMUNE MODULATORS TO IMPROVE NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114126608-A | Use of immunomodulators to improve nerve regeneration | 得克萨斯州大学系统董事会 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | CXCR3, CXCL12, CXCR4 | PAH 4879/4885KDM4E 3304/4885MAPT 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.